Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry

Fig. 2

Disease activity according to DAS28-ESR at baseline and after 1 year of treatment. DAS28-ESR, 28-joint disease activity score with erythrocyte sedimentation; REM, remission; LDA, low disease activity; MDA, moderate disease activity; HDA, high disease activity; IQR, interquartile range

Back to article page